Tumour necrosis factor receptor-associated periodic syndrome
Also known as: TNF-receptor Associated Periodic Syndromes (TRAPS) / Tumor necrosis factor receptor-associated periodic syndrome / Tumor necrosis factor receptor-associated periodic fever syndrome (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB06168 | Canakinumab | An interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA). |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB06168 | Canakinumab | Interleukin-1 beta | target |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB06168 | Canakinumab | 2 | Completed | 1 |